Inhibition of PAI-1 may be an effective therapeutic strategy to reduce vascular stiffness by modulating actin polymerization in smooth muscle cells.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Christopher P. Mack (2024) conducted an editorial in Vascular stiffness. PAI-1 inhibitor (PAI-039 / tiplaxtinin) was evaluated on Vascular stiffness.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: